Merck Current Ratio 2010-2022 | MRK

Current and historical current ratio for Merck (MRK) from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Merck current ratio for the three months ending June 30, 2022 was 1.39.
Merck Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-06-30 $32.12B $23.17B 1.39
2022-03-31 $31.18B $22.32B 1.40
2021-12-31 $30.27B $23.87B 1.27
2021-09-30 $31.06B $23.73B 1.31
2021-06-30 $28.67B $21.91B 1.31
2021-03-31 $26.91B $26.36B 1.02
2020-12-31 $27.76B $27.33B 1.02
2020-09-30 $26.58B $20.41B 1.30
2020-06-30 $29.34B $22.18B 1.32
2020-03-31 $26.17B $23.48B 1.12
2019-12-31 $27.48B $22.22B 1.24
2019-09-30 $26.14B $20.68B 1.26
2019-06-30 $24.30B $20.09B 1.21
2019-03-31 $25.35B $18.54B 1.37
2018-12-31 $25.88B $22.21B 1.17
2018-09-30 $26.84B $18.59B 1.44
2018-06-30 $24.06B $18.13B 1.33
2018-03-31 $24.09B $16.96B 1.42
2017-12-31 $24.77B $18.61B 1.33
2017-09-30 $27.92B $19.47B 1.43
2017-06-30 $28.17B $18.76B 1.50
2017-03-31 $31.53B $19.82B 1.59
2016-12-31 $30.61B $17.20B 1.78
2016-09-30 $29.44B $15.56B 1.89
2016-06-30 $27.93B $14.92B 1.87
2016-03-31 $28.77B $17.57B 1.64
2015-12-31 $29.75B $19.20B 1.55
2015-09-30 $28.57B $17.58B 1.63
2015-06-30 $28.32B $17.51B 1.62
2015-03-31 $32.93B $20.44B 1.61
2014-12-31 $32.61B $18.40B 1.77
2014-09-30 $34.72B $25.93B 1.34
2014-06-30 $33.59B $17.93B 1.87
2014-03-31 $41.24B $22.47B 1.84
2013-12-31 $35.69B $17.87B 2.00
2013-09-30 $37.77B $18.22B 2.07
2013-06-30 $37.00B $18.40B 2.01
2013-03-31 $35.24B $18.80B 1.87
2012-12-31 $34.86B $18.35B 1.90
2012-09-30 $36.23B $15.58B 2.33
2012-06-30 $35.64B $16.91B 2.11
2012-03-31 $34.34B $16.58B 2.07
2011-12-31 $33.18B $16.25B 2.04
2011-09-30 $34.11B $16.59B 2.06
2011-06-30 $32.37B $15.76B 2.05
2011-03-31 $31.02B $15.66B 1.98
2010-12-31 $29.06B $15.64B 1.86
2010-09-30 $27.76B $17.32B 1.60
2010-06-30 $26.25B $15.42B 1.70
2010-03-31 $28.25B $16.46B 1.72
2009-12-31 $28.43B $15.64B 1.82
2009-09-30 $29.67B $8.03B 3.70
2009-06-30 $29.23B $11.51B 2.54
2009-03-31 $26.19B $13.42B 1.95
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $230.579B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $434.603B 16.55
Eli Lilly (LLY) United States $292.730B 37.12
Pfizer (PFE) United States $281.235B 8.24
AbbVie (ABBV) United States $252.131B 10.71
Novo Nordisk (NVO) Denmark $243.269B 32.09
Novartis AG (NVS) Switzerland $189.576B 13.98